<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613127</url>
  </required_header>
  <id_info>
    <org_study_id>BR-HAV-CT-303</org_study_id>
    <nct_id>NCT05613127</nct_id>
  </id_info>
  <brief_title>To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Multinational, Active-controlled, Parallel-designed Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24months to 15yrs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate immunogenicity and safety of inactivated hepatitis A&#xD;
      vaccine in healthy children aged from 24 months to 15 years when administered an initial dose&#xD;
      followed by a booster dose (a total of 2 doses administered with 6 months interval).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate immunogenicity and safety of inactivated hepatitis A&#xD;
      vaccine in healthy children aged from 24 months to 15 years when administered an initial dose&#xD;
      followed by a booster dose (a total of 2 doses administered with 6 months interval).&#xD;
&#xD;
      This study is a two-group comparative study using a marketed inactivated hepatitis A vaccine&#xD;
      (HAVRIX®, manufactured by GSK) as a control. The study will demonstrate non-inferiority of&#xD;
      the test vaccine compared to the control vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2022</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HAV seroconversion rate at 4 weeks after the second vaccination</measure>
    <time_frame>At Visit 6 (7 months after Day 1: first vaccination)</time_frame>
    <description>Seroconversion: anti-HAV ≥ 20 mIU/mL after the second vaccination in subjects with anti-HAV &lt; 20 mIU/mL at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMCs (Geometric Mean Concentrations) measured with anti-HAV antibody titers at before the first vaccination and 4 weeks after the second vaccination</measure>
    <time_frame>At Visit 6 (7 months after Day 1: first vaccination)</time_frame>
    <description>GMCs (Geometric Mean Concentrations) measured with anti-HAV antibody titers at before the first vaccination and 4 weeks after the second vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMR (Geometric Mean Ratio, GMC Visit 6/GMC Visit 1) measured with anti-HAV antibody titers at 4 weeks after the second vaccination compared to those before the first vaccination</measure>
    <time_frame>At Visit 6 (7 months after Day 1: first vaccination)</time_frame>
    <description>GMR (Geometric Mean Ratio, GMC Visit 6/GMC Visit 1) measured with anti-HAV antibody titers at 4 weeks after the second vaccination compared to those before the first vaccination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Hepatitis A</condition>
  <condition>Hep A</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated Hepatitis A vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inactivated Hepatitis A vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL</intervention_name>
    <description>Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HAVRIX 720 Junior 0.5 mL</intervention_name>
    <description>Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female children ≥ 24 months and ≤ 15 years old on the day of first&#xD;
             vaccination&#xD;
&#xD;
          2. Subjects with no history of hepatitis A and no previous vaccination against hepatitis&#xD;
             A&#xD;
&#xD;
          3. Written informed consent obtained from the subject's legal representative (parents or&#xD;
             representative)&#xD;
&#xD;
          4. Children who no health issues based on medical history and physical examination as&#xD;
             judged by the investigator&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Tympanic temperature of 38.0℃ or above within 48 hours prior to vaccination or on the&#xD;
             day of vaccination&#xD;
&#xD;
          2. Uncontrolled epilepsy or neurological disorder&#xD;
&#xD;
          3. History of thrombocytopenia or has a risk of bleeding&#xD;
&#xD;
          4. History of hypersensitivity to the following: neomycin, formaldehyde, gentamicin&#xD;
             sulfate, any vaccine&#xD;
&#xD;
          5. Severe acute or chronic infectious disease on the day of vaccination&#xD;
&#xD;
          6. Congenital / acquired immunodeficiency or receiving immunosuppressive therapy&#xD;
&#xD;
          7. Received immunosuppressive dose of systemic corticosteroids within 12 weeks prior to&#xD;
             the first vaccination with the IP (Investigational Product) (equivalent potency of ≥&#xD;
             prednisolone 20 mg/day or equivalent potency of ≥ prednisolone 2.0 mg/kg/day in &lt; 10kg&#xD;
             of body weight for ≥ 14 consecutive days)&#xD;
&#xD;
          8. Administration of any other vaccine within 4 weeks prior to Screening&#xD;
&#xD;
          9. Planned administration of any other vaccine within 4 weeks after the last vaccination&#xD;
             of the investigational product&#xD;
&#xD;
         10. Administration of immunoglobulins or blood products or received blood transfusion&#xD;
             within 12 weeks prior to Screening&#xD;
&#xD;
         11. Currently participating in another clinical trial or administered / applied other&#xD;
             investigational product / medical device within 6 months prior to Screening&#xD;
&#xD;
         12. Ineligibility for participate in the study for other reasons as determined by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seoyeon Hong, BS</last_name>
    <phone>+82-2-740-4087</phone>
    <email>brbio_co@boryungbio.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hari Jeon, PharmD</last_name>
    <phone>+82-2-740-4228</phone>
    <email>hrjeon@boryungbio.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic University of Korea, ST. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Jong-Hyun Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Tavitiya Sudjaritruk, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis A</keyword>
  <keyword>Hepatitis A vaccine</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Hep A</keyword>
  <keyword>HAV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

